Aleksandar Vitomirov

Associate

Aleks Vitomirov is an associate in Wilson Sonsini Goodrich & Rosati’s Century City office. His practice focuses on technology transactions and corporate law matters.

As an undergraduate student, Aleks conducted bioinformatics research on the protein, dematin, providing him with research experience in bioinformatics and biochemistry.

In addition to fluently speaking English, Aleks fluently speaks Serbian.

Experience

Aleks Vitomirov is an associate in Wilson Sonsini Goodrich & Rosati’s Century City office. His practice focuses on technology transactions and corporate law matters.

As an undergraduate student, Aleks conducted bioinformatics research on the protein, dematin, providing him with research experience in bioinformatics and biochemistry.

In addition to fluently speaking English, Aleks fluently speaks Serbian.

Education

J.D., Santa Clara University School of Law, 2021
Order of the Coif
B.A., Biochemistry, University of San Diego, 2016

Admissions

State Bar of California

Credentials

Education

J.D., Santa Clara University School of Law, 2021
Order of the Coif
B.A., Biochemistry, University of San Diego, 2016

Admissions

State Bar of California

Recent Insights

Client Highlights

On October 17, 2024, Terray Therapeutics, a Los Angeles-based biotechnology company improving human health by enhancing small molecule drug development, announced that it raised $120 million in Series B funding. The round was led by Bedford Ridge Capital and existing investor NVentures (NVIDIA’s venture capital arm), with participation from new and existing investors, including Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. Wilson Sonsini Goodrich & Rosati advised Terray on the transaction.

Learn More

Client Highlights

On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.

Learn More

View All

Recent Events

Affiliated Programs

Wilson Sonsini is the proud presenting sponsor of #EarlyStageLA. Join us for an exciting and dynamic evening at the Startup Launchpad, where innovation meets opportunity and investment. This event is tailored for growing startups seeking to raise capital, scale their businesses, and connect with potential investors. Attendees will gain invaluable insights from industry leaders in technology, finance, legal, and HR, as well as opportunities to pitch their companies to investors and forge strategic partnerships.

Learn More

Affiliated Programs

Wilson Sonsini is the proud presenting sponsor of Early Stage Los Angeles. Join us for the #EarlyStageLA Launch Party, a landmark event designed to kickstart a transformative initiative for early-stage startups in the Los Angeles metropolitan area. This event marks the beginning of the city-wide effort to activate brand partnerships, venture capital funds, accelerators, universities, and promising startups, driving significant investment into the region's entrepreneurial ecosystem.

Learn More